Summary
2.79 -0.11(-3.78%)05/15/2024
Aspira Women`s Health Inc (AWH)
Aspira Women`s Health Inc (AWH)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -8.10 | -8.39 | 4.61 | -31.55 | -34.15 | 865.31 | 137.90 | -99.17 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 2.95 | |
| Open | 3.25 | |
| High | 3.25 | |
| Low | 2.94 | |
| Volume | 52,203 | |
| Change | -0.26 | |
| Change % | -8.10 | |
| Avg Volume (20 Days) | 13,890 | |
| Volume/Avg Volume (20 Days) Ratio | 3.76 | |
| 52 Week Range | 0.22 - 6.75 | |
| Price vs 52 Week High | -56.30% | |
| Price vs 52 Week Low | 1,240.91% | |
| Range | -9.23 | |
| Gap Up/Down | -0.03 | |
Fundamentals | ||
| Market Capitalization (Mln) | 34 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 12.00 | |
| Book Value | 0.3430 | |
| Earnings Per Share | -0.2660 | |
| EPS Estimate Current Quarter | -0.0700 | |
| EPS Estimate Next Quarter | -0.0700 | |
| EPS Estimate Current Year | -0.2500 | |
| EPS Estimate Next Year | -0.2700 | |
| Diluted EPS (TTM) | -0.2660 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -4.6391 | |
| Return on asset (TTM) | -0.5360 | |
| Return on equity (TTM) | -1.0850 | |
| Revenue TTM | 6,407,000 | |
| Revenue per share TTM | 0.0590 | |
| Quarterly Revenue Growth (YOY) | 0.3450 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 1,236,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.1253 | |
| Revenue Enterprise Value | 24.3269 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 112,127,000 | |
| Shares Float | 66,505,620 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 47.97 | |
| Institutions (%) | 28.50 | |
05/15 11:50 EST - seekingalpha.com
Aspira Women's Health Inc. (AWH) Q1 2024 Earnings Call Transcript
Aspira Women's Health Inc. (NASDAQ:AWH ) Q1 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Nicole Sandford - CEO Sandy Milligan - President Torsten Hombeck - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Maggie Boeye - William Blair Do Kim - Water Tower Research Operator Good morning, ladies and gentlemen, and welcome to Aspira Women's Health, Incorporated. First Quarter 2024 Earnings Conference Call.
Aspira Women's Health Inc. (AWH) Q1 2024 Earnings Call Transcript
Aspira Women's Health Inc. (NASDAQ:AWH ) Q1 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Nicole Sandford - CEO Sandy Milligan - President Torsten Hombeck - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Maggie Boeye - William Blair Do Kim - Water Tower Research Operator Good morning, ladies and gentlemen, and welcome to Aspira Women's Health, Incorporated. First Quarter 2024 Earnings Conference Call.
05/15 09:40 EST - zacks.com
Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates
Aspira (AWH) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $10.94 per share a year ago.
Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates
Aspira (AWH) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $10.94 per share a year ago.
05/15 07:30 EST - globenewswire.com
Aspira Women's Health Reports First Quarter 2024 Financial Results
Q1 2024 OvaSuite S M revenue of $2.2 million and volume of 5,829 units
Aspira Women's Health Reports First Quarter 2024 Financial Results
Q1 2024 OvaSuite S M revenue of $2.2 million and volume of 5,829 units
05/08 08:47 EST - globenewswire.com
UPDATE -- Aspira Women's Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024. Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows:
UPDATE -- Aspira Women's Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024. Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows:
05/08 08:00 EST - globenewswire.com
Aspira Women's Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024. Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows:
Aspira Women's Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024. Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows:
04/09 08:00 EST - globenewswire.com
Aspira Women's Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California
Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid
Aspira Women's Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California
Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid
03/28 11:37 EST - seekingalpha.com
Aspira Women's Health Inc. (AWH) Q4 2023 Earnings Call Transcript
Aspira Women's Health Inc. (AWH) Q4 2023 Earnings Call Transcript
Aspira Women's Health Inc. (AWH) Q4 2023 Earnings Call Transcript
Aspira Women's Health Inc. (AWH) Q4 2023 Earnings Call Transcript
03/28 07:30 EST - globenewswire.com
Aspira Women's Health Reports Fourth Quarter and Full Year 2023 Financial Results
2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth quarter and full-year 2023 to $3.5 million and $15.9 million, respectively Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2023. “We made a great deal of progress in 2023.
Aspira Women's Health Reports Fourth Quarter and Full Year 2023 Financial Results
2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth quarter and full-year 2023 to $3.5 million and $15.9 million, respectively Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2023. “We made a great deal of progress in 2023.
03/21 08:00 EST - globenewswire.com
Aspira Women's Health to Present at the MedInvest Biotech & Pharma Investor Conference
AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference taking place in New York City on April 3-4, 2024. Management will be available for one-on-one meetings with investors who are registered for the conference.
Aspira Women's Health to Present at the MedInvest Biotech & Pharma Investor Conference
AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference taking place in New York City on April 3-4, 2024. Management will be available for one-on-one meetings with investors who are registered for the conference.
03/11 08:00 EST - globenewswire.com
Aspira Women's Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024. Management will also host a conference call at 4:30 pm to discuss financial results and provide a corporate update. Details for the call are as follows:
Aspira Women's Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024. Management will also host a conference call at 4:30 pm to discuss financial results and provide a corporate update. Details for the call are as follows:
02/22 08:30 EST - GlobeNewsWire
Aspira Women's Health to Present at The Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at The Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference taking place in New Orleans, Louisiana on February 29 to March 2, 2024. Management will be available for one-on-one meetings with investors who are registered for the conference.
Aspira Women's Health to Present at The Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at The Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference taking place in New Orleans, Louisiana on February 29 to March 2, 2024. Management will be available for one-on-one meetings with investors who are registered for the conference.
02/12 08:00 EST - globenewswire.com
Aspira Women's Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)
AUSTIN, Texas, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced a late-breaking poster presentation at the upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI) to be held in Vancouver, Canada on March 12-16, 2024.
Aspira Women's Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)
AUSTIN, Texas, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced a late-breaking poster presentation at the upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI) to be held in Vancouver, Canada on March 12-16, 2024.
12/19 08:00 EST - globenewswire.com
Aspira Women's Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024
AUSTIN, Texas, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it will host a virtual R&D day featuring experts who will present the exciting progress of the company's product pipeline on January 4, 2024 at 11:00 AM ET. To register, click here.
Aspira Women's Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024
AUSTIN, Texas, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it will host a virtual R&D day featuring experts who will present the exciting progress of the company's product pipeline on January 4, 2024 at 11:00 AM ET. To register, click here.
12/14 08:00 EST - globenewswire.com
Aspira Women's Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024
AUSTIN, Texas, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will be available for partnering and institutional one-on-one meetings in San Francisco, during JP Morgan's Healthcare Conference Week 2024. Nicole Sandford, President and Chief Executive Officer, in addition to Torsten Hombeck, Ph.D., Chief Financial Officer from the management team will be in attendance at the following corporate access and partnering events:
Aspira Women's Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024
AUSTIN, Texas, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will be available for partnering and institutional one-on-one meetings in San Francisco, during JP Morgan's Healthcare Conference Week 2024. Nicole Sandford, President and Chief Executive Officer, in addition to Torsten Hombeck, Ph.D., Chief Financial Officer from the management team will be in attendance at the following corporate access and partnering events:
12/06 08:00 EST - globenewswire.com
Aspira Women's Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis
Data supports EndoCheck™ to be the first blood test for the identification of localized endometriosis, including endometrioma
Aspira Women's Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis
Data supports EndoCheck™ to be the first blood test for the identification of localized endometriosis, including endometrioma
11/28 08:00 EST - globenewswire.com
Aspira Women's Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)
California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per test California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per test
Aspira Women's Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)
California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per test California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per test
11/27 09:47 EST - globenewswire.com
Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)
CMS approves OvaWatch SM 2024 price at $897 per test AUSTIN, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women's health diagnostic tools for gynecologic diseases, today announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS) rate setting process, the Centers for Medicare & Medicaid Services (CMS) has approved the crosswalk of the fee to be paid to the company for OvaWatch to the fee paid historically for Ova1. Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning on January 1, 2024.
Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)
CMS approves OvaWatch SM 2024 price at $897 per test AUSTIN, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women's health diagnostic tools for gynecologic diseases, today announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS) rate setting process, the Centers for Medicare & Medicaid Services (CMS) has approved the crosswalk of the fee to be paid to the company for OvaWatch to the fee paid historically for Ova1. Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning on January 1, 2024.
11/13 19:37 EST - seekingalpha.com
Aspira Women's Health Inc. (AWH) Q3 2023 Earnings Call Transcript
Aspira Women's Health Inc. (NASDAQ:AWH ) Q3 2023 Earnings Call November 13, 2023 4:30 PM ET Company Participants Nicole Sandford - President and Chief Executive Officer Torsten Hombeck - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Good afternoon, ladies and gentlemen, and welcome to the Aspira Women's Health Incorporated Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Aspira Women's Health Inc. (AWH) Q3 2023 Earnings Call Transcript
Aspira Women's Health Inc. (NASDAQ:AWH ) Q3 2023 Earnings Call November 13, 2023 4:30 PM ET Company Participants Nicole Sandford - President and Chief Executive Officer Torsten Hombeck - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Good afternoon, ladies and gentlemen, and welcome to the Aspira Women's Health Incorporated Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
11/09 08:00 EST - globenewswire.com
Aspira Women's Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch
The proposed rule would allow for OvaWatch SM to be reimbursed at the same rate as Ova1 ® at $897 per test and will become final following a brief public comment period
Aspira Women's Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch
The proposed rule would allow for OvaWatch SM to be reimbursed at the same rate as Ova1 ® at $897 per test and will become final following a brief public comment period
10/25 08:00 EST - globenewswire.com
Aspira Women's Health Sees Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research
Data showed miRNA-protein models potential to improve the diagnostic accuracy of non-invasive ovarian cancer tests Data showed miRNA-protein models potential to improve the diagnostic accuracy of non-invasive ovarian cancer tests
Aspira Women's Health Sees Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research
Data showed miRNA-protein models potential to improve the diagnostic accuracy of non-invasive ovarian cancer tests Data showed miRNA-protein models potential to improve the diagnostic accuracy of non-invasive ovarian cancer tests